A6733

Auranofin

≥98% (HPLC), powder, leukocyte activation pathway inhibitor

• Sinônimo(s): 1-Thio-β-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate, 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium, SKF 39162
• Fórmula empírica (Notação de Hill): C₂₀H₃₄AuO₉PS
• Número CAS: 34031-32-8
• Peso molecular: 678.48
• Número CE: 251-801-9
• Número MDL: MFCD00080759
• Código UNSPSC: 51111800
• ID de substância PubChem: 329770903
• NACRES: NA.77

Propriedades

• Nome do produto: Auranofin, ≥98% (HPLC)
• Ensaio: ≥98% (HPLC)
• Formulário: powder
• solubilidade: DMSO: ≥5 mg/mL
• originador: Prometheus
• temperatura de armazenamento: room temp
• cadeia de caracteres SMILES: CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
• InChI: 1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1/t10-,11-,12+,13-,14+;;/m1../s1
• chave InChI: AUJRCFUBUPVWSZ-XTZHGVARSA-M

Descrição

Aplicação

Auranofin inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin also inhibits 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5 and selenoenzyme thioredoxin reductase (TrxR) which is involved in the defense against oxidative stress. Auranofin is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.

Ações bioquímicas/fisiológicas

Auranofin inhibits various leukocyte activation pathways at multiple sites and is a disease-modifying antirheumatic drug (DMARD).

Auranofin inhibits various leukocyte activation pathways at multiple sites. Auranofin inhibits the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. The compound also inhibits 5-lipoxygenase in human neutrophils. Auranofin is a disease-modifying antirheumatic drug (DMARD). The compound is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress. Auranofin is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase. Auranofin inhibits IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5.

Características e benefícios

This compound was developed by Prometheus. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informações de segurança

• Pictogramas: GHS06,GHS08
• Palavra indicadora: Danger
• Frases de perigo: H301,H361
• Declarações de precaução: P202 - P264 - P270 - P280 - P301 + P310 - P405
• Classificações de perigo: Acute Tox. 3 Oral - Repr. 2
• Código de classe de armazenamento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable
• Equipamento de proteção individual: dust mask type N95 (US), Eyeshields, Faceshields, Gloves